There were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 - a high-risk age range for
The post Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 – Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market appeared first on The Center.
Smoking Cessation Feeds
http://ift.tt/1PDRweS June 9, 2016 at 12:31AM
No comments:
Post a Comment